Tongji Medical College

IASO Bio and Innovent Present New Data of FUCASO® (Equecabtagene Autoleucel) for Multiple Myeloma Patients in Oral Presentation at ASH 2023

Retrieved on: 
Monday, December 11, 2023
Huachung University, Multiple myeloma, Triple, Ophthalmology, HKEX, Safety, SAN, Hope, Treatment, Progression-free survival, ASH, Risk, Tongji Hospital station, Tongji Medical College, Patient, PFS, MRD, Marketing, Trial of the century, Medicine, VCN, Prognosis, Peking Union Medical College, ORR, Cancer, Survival, RRMM, BCMA, Quality of life, Society, Autoimmunity, Pharmaceutical industry, Medical device, Vaccine, Hematology

The presentation highlights the characteristics and efficacy of fully human BCMA-targeting CAR-T (Equecabtagene Autoleucel) on multiple myeloma patients who had sustained minimal residual disease (MRD) negativity after receiving treatment.

Key Points: 
  • The presentation highlights the characteristics and efficacy of fully human BCMA-targeting CAR-T (Equecabtagene Autoleucel) on multiple myeloma patients who had sustained minimal residual disease (MRD) negativity after receiving treatment.
  • As of December 31, 2022, with a median follow-up of 18.07 months, deep and sustained responses were observed in 103 evaluable patients.
  • Among these patients, the overall response rate (ORR) was 96.1%, and the stringent complete response/complete response (sCR/CR) rate was 77.7%.
  • Minimal residual disease (MRD) negativity rate is 94.2% in the total evaluable patients, and all patients who achieved CR or above were MRD negative.

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

Retrieved on: 
Monday, August 21, 2023
Huazhong University of Science and Technology, Bleeding, Hematology, SC, Medicine, New Drug Application, NDA, ITP, Huachung University, Committee, Breakthrough therapy, Tongji Medical College, HKEX, Peking Union Medical College, The Lancet, Patient, Risk, Union Hospital, National Medical Products Administration, Principal, Safety, NMPA, Wuhan Union Hospital, Disease, Bone marrow, Pharmaceutical industry, Nursing, FC, MD

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 20, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the pivotal Phase III trial ESLIM-01 evaluating the investigational use of sovleplenib met its primary endpoint of durable response rate and all secondary endpoints in adult patients with primary immune thrombocytopenia (“ITP”) in China. HUTCHMED plans to submit the New Drug Application (“NDA”) around the end of 2023.

Key Points: 
  • The National Medical Products Administration of China (“NMPA”) granted Breakthrough Therapy designation (“BTD”) to sovleplenib for the indication studied in ESLIM-01 in January 2022.
  • As such, the sovleplenib NDA may be considered for priority review for its use in ITP.
  • ESLIM-01 is a randomized, double-blinded, placebo-controlled Phase III trial in China of sovleplenib in 188 adult patients with primary ITP who have received at least one prior line of standard therapy.
  • Sovleplenib is a novel, selective, oral inhibitor targeting spleen tyrosine kinase (“Syk”) for the treatment of hematological malignancies and immune diseases.

IASO Bio and Innovent Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel（BCMA CAR-T Cell Therapy）for Multiple Myeloma at the 2023 ASCO Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Tongji Hospital station, DNA, Fragment crystallizable region, Pi, Biotechnology, SCR, CRS, Hook effect, DOR, B-cell maturation antigen, American Society of Clinical Oncology, Bone marrow, Huachung University, Cmax, Doctor of Philosophy, PFS, Trial of the century, MTTR, ASCO, MRD, CAR, Tongji Medical College, CR, Congress, Multiple myeloma, MD, Patient, Cytokine release syndrome, SAN, EMM, Annual general meeting, Immunotherapy, EHA, MM, RRMM, Huazhong University of Science and Technology, Proteasome inhibitor, Society, ADA, ORR, BCMA, Safety, Center for Innovative Phage Applications and Therapeutics, Disease, Vaccine, Pharmaceutical industry

The updated data showed long-term follow-up efficacy and safety of the phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China.

Key Points: 
  • The updated data showed long-term follow-up efficacy and safety of the phase 1b/2 study (FUMANBA-1) conducted in 14 centers in China.
  • Among the 103 patients, 68.9% (71/103) had high-risk cytogenetic abnormalities per mSMART 3.0, 12.6%（13/103）had extramedullary multiple myeloma (EMM), and 11.7%（12/103）had received prior CAR-T therapy.
  • Equecabtagene Autoleucel demonstrated a favorable and manageable safety profile: Among the 103 patients, 93.2% (96/103) experienced cytokine release syndrome (CRS).
  • These results are encouraging and entails an opportunity to advance Equecabtagene Autoleucel to earlier lines of treatment to benefit more MM patients."

Soricimed Appoints Leading North American Cancer Researcher Dr. Siqing Fu to its Scientific Advisory Board

Retrieved on: 
Tuesday, December 13, 2022
Therapy, Peptide, Paralysis, TRPV6, Oncology, Hematology, Food, II, MD, Regulation of tobacco by the U.S. Food and Drug Administration, University, Cancer, Section, Research, MD Anderson Cancer Center, Tongji Medical College, Disease, Division, Coronavirus Scientific Advisory Board (Turkey), Christian democracy, Pharmaceutical industry, NB

MONCTON, NB, Dec. 13, 2022 /CNW/ - Soricimed Biopharma Inc., ("Soricimed" or "the Company"), a clinical stage company focused on the development and commercialization of first-in-class targeted cancer therapeutics, has appointed Dr. Siqing Fu, a North American leader in cancer research, to its Scientific Advisory Board.

Key Points: 
  • MONCTON, NB, Dec. 13, 2022 /CNW/ - Soricimed Biopharma Inc., ("Soricimed" or "the Company"), a clinical stage company focused on the development and commercialization of first-in-class targeted cancer therapeutics, has appointed Dr. Siqing Fu, a North American leader in cancer research, to its Scientific Advisory Board.
  • "We are honoured to have Dr. Fu join our Scientific Advisory Board at this pivotal time for our company," said Robert Bruce, Chief Executive Officer of Soricimed.
  • "He brings extensive experience to the research table including investigational cancer therapies specifically in novel design for phase I and II clinical trials.
  • "I am pleased to be joining Soricimed as a scientific advisor," said Dr. Fu.

Fuheng Herbs Announces New Business Location and New Chinese Herbal Medicine Store to Better Meet the Needs of Patients in the Silicon Valley Community

Retrieved on: 
Friday, November 11, 2022
Shoulder, Health, NEW, Fuheng, 2000 Goody's Body Pain 500, Traditional Chinese medicine, CA, Acupuncture, Diagnosis, Prostate cancer, Back pain, Pain, Infertility, Huachung University, Family, Cancer, Knowledge, Darkness, Research, Silicon, Pharmacy, Apple, Neck, Patient, TCM, Herbal medicine, Diabetes, Method, Prescription, Tongji Medical College, News, Herbal, Technology, Time, Medicine, Hypertension, Medicinal plants, Medical device, Dentistry, Google

"The new location marks an important step to better provide services and treatments to patients," said Dr. Dalong Zhang, founder of Fuheng Herbs.

Key Points: 
  • "The new location marks an important step to better provide services and treatments to patients," said Dr. Dalong Zhang, founder of Fuheng Herbs.
  • Dr. Zhang used Chinese medicine diagnosis techniques and designed a treatment plan which included energy therapy, acupuncture, and Chinese herbs.
  • Fuheng Herbs develops and manufactures Chinese herbal supplements and herbal teas and distributes Chinese herbs.
  • He recently launched his flagship Chinese herbal medicine store, providing patients in the Silicon Valley community the convenience of getting their herbal teas, supplements, and herbs 24x7.

Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer

Retrieved on: 
Wednesday, November 9, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Neuromuscular Disorders, Research, Hematology, FAQ, Therapy, Berkeley, Molecular biology, Medical University of South Carolina, Company, Human, Medical school, Security (finance), Securities Act of 1933, Arcturus, Industry, Acceleron Pharma, Review, Tongji Medical College, Multimedia, U.S. Securities and Exchange Commission, DRAGON, Takeda Oncology, Global Affairs Canada, Cancer, Patient, Social media, SAPPHIRE, Gongshi, ARCT, COVID-19, Investor, Private Securities Litigation Reform Act, Fibrosis, Medical Affairs Bureau, Risk, Nephrology, Alnylam Pharmaceuticals, R, Clinical trial, Degenerative disease, Growth, Executive, Arcturus Therapeutics, SMA, Intellectual property, Rock, File, Doctor of Philosophy, Biogen, NASDAQ, Safety, University, Neurology, Public relations, Pharmaceutical industry, Biochemistry, Alexion

View the full release here: https://www.businesswire.com/news/home/20221109005240/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221109005240/en/
    We are thrilled to welcome Jing to Scholar Rock as Chief Medical Officer.
  • Her broad and deep expertise in leading development and medical affairs will be instrumental in helping us advance our clinical programs and differentiated platform in targeting the TGF superfamily, said Jay Backstrom, M.D., M.P.H., Chief Executive Officer of Scholar Rock.
  • Most recently, Dr. Marantz served as the Executive Vice President and Chief Business Officer at Krystal Biotech.
  • Scholar Rock is a registered trademark of Scholar Rock, Inc.

Tongji Hospital Begins Installation of Mevion Proton Therapy System

Retrieved on: 
Thursday, August 4, 2022
Research, Hospitals, Health Technology, Other Health, Health, General Health, Other Science, Science, Oncology, Proton, Neoplasm, Varian Medical Systems, Proton therapy, Education, NMPA, PET/CT, PBS, Technology, Central, Tongji Hospital station, National Medical Products Administration, Patient, Multimedia, Huachung University, Tongji Medical College, Scan (company), Hospital, LinkedIn, Research, Science, Cancer, Faculty, Tongji, Risk, Huazhong University of Science and Technology, Partnership, Growth, Medical imaging, Central China

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that the accelerator for the MEVION S250i Proton Therapy System was delivered on July 28, 2022, to Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China.

Key Points: 
  • Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that the accelerator for the MEVION S250i Proton Therapy System was delivered on July 28, 2022, to Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology in Wuhan, China.
  • This milestone commences the system installation at Tongji Hospitals proton therapy center, the first of its kind in Central China.
  • View the full release here: https://www.businesswire.com/news/home/20220804005161/en/
    Mevion begins system installation at Tongji Hospital in Wuhan, China (Photo: Business Wire)
    The system at Tongji Hospital features Mevions industry leading HYPERSCAN Pencil Beam Scanning (PBS) technology and Adaptive Aperture pMLC.
  • Mevions flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the worlds smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems.

Tongji hospital selects RayStation

Retrieved on: 
Thursday, April 7, 2022
Proton, RaySearch Laboratories, Karolinska Institute, Tongji Hospital station, Electron, Proton therapy, OIS, Education, Research, HDR, Cancer, Carbon, OAS, Huachung University, Tongji Medical College, Nasdaq Stockholm, Photon, Industry, TPS, Helium, TCS, Ion, Huazhong University of Science and Technology, Technology, Patient, Medical imaging, Weapon

STOCKHOLM, April 7, 2022 /PRNewswire/ --RaySearch Laboratories AB (publ) announces that Mevion China has placed an order for RayStation* which Mevion China has sold together with Mevion's HYPERSCAN proton therapy system to Tongji Hospital in Wuhan in China.

Key Points: 
  • STOCKHOLM, April 7, 2022 /PRNewswire/ --RaySearch Laboratories AB (publ) announces that Mevion China has placed an order for RayStation* which Mevion China has sold together with Mevion's HYPERSCAN proton therapy system to Tongji Hospital in Wuhan in China.
  • RaySearch has about 70 RayStation customers in China through its own subsidiary in the country.
  • Tongji Hospital, Tongji Medical College and Huazhong University of Science & Technology are located in Wuhan in the Hubei Province of China.
  • Tongji Hospital was founded by the German doctor Erich Paulun in Shanghai in 1900.

Mevion Selected to Equip Proton Therapy Center at Tongji Hospital in China

Retrieved on: 
Monday, February 21, 2022
Oncology, Education, Health, Medical Devices, Hospitals, University, Biotechnology, Proton, Risk, Huachung University, Tongji Hospital station, Growth, Scan (company), Education, Adaptation, Varian Medical Systems, Proton therapy, Neoplasm, Huazhong University of Science and Technology, Tongji, Multimedia, Science, Tongji Medical College, Patient, U.S. News & World Report Best Hospitals Rankings, PBS, Faculty, LinkedIn, Research, Medical imaging, Medicine, Central China, Technology, Mevion Medical Systems, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, MEVION MEDICAL SYSTEMS, TONGJI HOSPITAL OF TONGJI MEDICAL COLLEGE, HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY

Mevion Medical Systems today announced it has been selected by Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology to equip their new proton therapy center with a MEVION S250i Proton Therapy System in Wuhan, China.

Key Points: 
  • Mevion Medical Systems today announced it has been selected by Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology to equip their new proton therapy center with a MEVION S250i Proton Therapy System in Wuhan, China.
  • Founded in 1900 and listed as the 6th top hospital in Fudans 2020 China Hospital Ranking , Tongji Hospital provides over 6 million annual outpatient visits.
  • The contract for the new proton therapy center was completed in late 2021, and construction of the new 135,000 square-foot proton therapy center at Tongji Hospitals Optics Valley campus is expected to be completed by December 2022.
  • Mevions flagship product, the MEVION S250i Proton Therapy System with HYPERSCAN pencil beam scanning, is the worlds smallest proton therapy system that eliminates the obstacles of size, complexity, and cost that exists with other proton therapy systems.

A New Test Could Improve Diagnosis of Male Infertility and Advance Fertility Treatment

Retrieved on: 
Friday, January 21, 2022
Semen, Research, Patient, Pediatrics, Tongji Medical College, DFI, Incidence, Fertility, Knowledge, Clinical chemistry, DNA, Health, AACC, View, Mass spectrometry, MDB, DNA fragmentation, Infertility, Diagnosis, Doctor of Philosophy, Pregnancy, DNA repair, Male, Therapeutic drug monitoring, Genetic testing, Physician, Birth control

This new method could significantly improve diagnosis of male infertility, which is more important than ever now that infertility rates are mounting.

Key Points: 
  • This new method could significantly improve diagnosis of male infertility, which is more important than ever now that infertility rates are mounting.
  • The global incidence of infertility is now 10%-15%, with male factor infertility accounting for 40% of these cases.
  • Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation.
  • This vital research is advancing areas of healthcare ranging from genetic testing and drug monitoring to pediatrics and appropriate test utilization.